Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity-Reference-Cited by-同舟云学术

Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity

Published:2020-03-01 Issue:2 Volume:40 Page:101-113
ISSN:2234-3806
Container-title:Annals of Laboratory Medicine
language:en
Short-container-title:Ann Lab Med

Author:

Benucci Maurizio¹^ORCID,Grossi Valentina²^ORCID,Manfredi Mariangela²^ORCID,Damiani Arianna¹^ORCID,Infantino Maria²^ORCID,Moscato Paolo³^ORCID,Cinquanta Luigi⁴^ORCID,Gremese Elisa⁵⁶^ORCID,Tolusso Barbara⁵^ORCID,Petricca Luca⁵^ORCID,Fedele Anna Laura⁵^ORCID,Alivernini Stefano⁵⁶^ORCID,Atzeni Fabiola⁷^ORCID,Minisola Giovanni⁸^ORCID,Verna Roberto⁹¹⁰^ORCID

Affiliation:

1. Rheumatology Unit, S.Giovanni di Dio Hospital, Florence, Italy

2. Immunology and Allergology Laboratory Unit, S.Giovanni di Dio Hospital, Florence, Italy

3. Department of Medicine, University Hospital San Giovanni di Dio e Ruggi d’Aragona, Salerno, Italy

4. SDN SPA-Synlab Laboratory, Pagani, Salerno, Italy

5. Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy

6. Division of Rheumatology, Università Cattolica del Sacro Cuore, Rome, Italy

7. Rheumatology Unit, University of Messina, Messina, Italy

8. Italian Society of Rheumatology, Milan, Italy

9. World Association of Societies of Pathology and Laboratory Medicine, Milan, Italy

10. Department of Experimental Medicine Sapienza University of Rome, Rome, Italy

Publisher

Annals of Laboratory Medicine

Subject

Biochemistry, medical,Clinical Biochemistry,General Medicine

Link

https://synapse.koreamed.org/pdf/10.3343/alm.2020.40.2.101

Reference94 articles.

1. World Health Organization. International nonproprietary names (INN) for biological and biotechnological substances. Updated 2018. http://www.webcitation.org/6rGAZvnd2

2. Biologics-Based Therapy for the Treatment of Rheumatoid Arthritis

3. U.S. Food and Drug Administration. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product-draft guidance. United States Food and Drug Administration. Updated on Jun 2019. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf

5. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and validation of a novel therapeutic drug monitoring-based nomogram for prediction of primary endoscopic response to anti-TNF therapy in active Crohn’s disease;Therapeutic Advances in Gastroenterology;2024-01

2. Long-Term Retention Rate of Tofacitinib in Rheumatoid Arthritis: An Italian Multicenter Retrospective Cohort Study;Medicina;2023-08-17

3. Anti-Drug Antibodies in the Biological Therapy of Autoimmune Rheumatic Diseases;Journal of Clinical Medicine;2023-05-04

4. From alchemy to personalised medicine: the journey of laboratory medicine;Journal of Clinical Pathology;2023-02-24

5. Proposal of International Council for Harmonization (ICH) Guideline for the Approval of Biosimilars;Journal of Market Access & Health Policy;2022-11-17